1. Home
  2. MMS vs ALKS Comparison

MMS vs ALKS Comparison

Compare MMS & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MMS
  • ALKS
  • Stock Information
  • Founded
  • MMS 1975
  • ALKS 1987
  • Country
  • MMS United States
  • ALKS Ireland
  • Employees
  • MMS N/A
  • ALKS N/A
  • Industry
  • MMS Business Services
  • ALKS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MMS Consumer Discretionary
  • ALKS Health Care
  • Exchange
  • MMS Nasdaq
  • ALKS Nasdaq
  • Market Cap
  • MMS 4.8B
  • ALKS 5.0B
  • IPO Year
  • MMS 1997
  • ALKS 1991
  • Fundamental
  • Price
  • MMS $83.12
  • ALKS $30.70
  • Analyst Decision
  • MMS Buy
  • ALKS Strong Buy
  • Analyst Count
  • MMS 1
  • ALKS 13
  • Target Price
  • MMS $90.00
  • ALKS $42.31
  • AVG Volume (30 Days)
  • MMS 460.5K
  • ALKS 2.3M
  • Earning Date
  • MMS 11-20-2025
  • ALKS 10-28-2025
  • Dividend Yield
  • MMS 1.44%
  • ALKS N/A
  • EPS Growth
  • MMS 12.65
  • ALKS 2.44
  • EPS
  • MMS 5.37
  • ALKS 2.02
  • Revenue
  • MMS $5,428,731,000.00
  • ALKS $1,521,338,000.00
  • Revenue This Year
  • MMS $3.80
  • ALKS N/A
  • Revenue Next Year
  • MMS $2.20
  • ALKS $1.59
  • P/E Ratio
  • MMS $15.48
  • ALKS $15.25
  • Revenue Growth
  • MMS 3.40
  • ALKS 1.08
  • 52 Week Low
  • MMS $63.77
  • ALKS $25.17
  • 52 Week High
  • MMS $93.73
  • ALKS $36.45
  • Technical
  • Relative Strength Index (RSI)
  • MMS 34.51
  • ALKS 52.10
  • Support Level
  • MMS $83.03
  • ALKS $28.47
  • Resistance Level
  • MMS $88.96
  • ALKS $32.11
  • Average True Range (ATR)
  • MMS 1.97
  • ALKS 1.30
  • MACD
  • MMS -0.45
  • ALKS -0.12
  • Stochastic Oscillator
  • MMS 30.27
  • ALKS 56.74

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

About ALKS Alkermes plc

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Share on Social Networks: